BridgeBio Pharma (BBIO) Change in Accured Expenses (2018 - 2026)

BridgeBio Pharma has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $4.6 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $4.6 million, up 56.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.5 million (up 127.74% YoY), and the FY2025 annual result was $77.8 million, up 358.08% from the prior year.
• Change in Accured Expenses came in at $4.6 million for Q1 2026 at BridgeBio Pharma, down from $24.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $26.4 million in Q3 2025 to a low of -$16.9 million in Q3 2022.
• The 5-year median for Change in Accured Expenses is $6.7 million (2024), against an average of $5.6 million.
• Across the five-year window, Change in Accured Expenses plunged 140.09% in 2022 and soared 450.83% in 2023, its largest moves.
• BridgeBio Pharma's Change in Accured Expenses stood at $1.4 million in 2022, then jumped by 450.83% to $7.7 million in 2023, then jumped by 48.65% to $11.4 million in 2024, then jumped by 117.25% to $24.8 million in 2025, then sank by 81.37% to $4.6 million in 2026.
• The last three Change in Accured Expenses figures came in at $4.6 million (Q1 2026), $24.8 million (Q4 2025), and $26.4 million (Q3 2025), per Business Quant data.